Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Harvard Business School
Boehringer Ingelheim

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,235,735

« Back to Dashboard

Summary for Patent: 6,235,735

Title: Morpholine and thiomorpholine tachykinin receptor antagonists
Abstract:Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
Inventor(s): Dorn; Conrad P. (Plainfield, NJ), Hale; Jeffrey J (Westfield, NJ), Finke; Paul E. (Milltown, NJ), Maccoss; Malcolm (Freehold, NJ), Mills; Sander G. (Woodbridge, NJ), Shah; Shrenik K. (Metuchen, NJ), Chambers; Mark Stuart (Watford, GB), Ladduwahetty; Tamara (Buckhurst Hill, GB), Harrison; Timothy (Great Dunmow, GB), Williams; Brian John (Great Dunnow, GB)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:09/526,843
Patent Claim Types:
see list of patent claims

No matches for this query

International Patent Family for Patent: 6,235,735

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2634372► Subscribe
JapanH09506628► Subscribe
JapanH06172178► Subscribe
Israel111960► Subscribe
Israel106142► Subscribe
Hungary224014► Subscribe
HungaryT76476► Subscribe
Hungary9601634► Subscribe
Hungary219713► Subscribe
HungaryT71809► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: